Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Chloroquine AND (Coronavirus 2019 OR COVID-19 OR SARS-CoV-2))
2,078 results
  • Nearly Fatal Hydroxychloroquine Overdose Successfully Treated with Midazolam, Propofol, Sodium Bicarbonate, Norepinephrine, and Intravenous Lipid Emulsion. [Case Reports]
    Case Rep Emerg Med. 2021; 2021:8876256.Onsia G, Bots S
  • CONCLUSIONS: Since high-quality scientific evidence is lacking, treatment options are based on experience in chloroquine toxicity. Activated charcoal is advised if the patient presents early. Sedation with diazepam, early ventilation, and continuous epinephrine infusion are considered effective in treating severe intoxication. Caution is advised when substituting potassium. Despite the lack of formal evidence, sodium bicarbonate appears to be useful and safe in case of QRS widening. Intravenous lipid emulsion, with or without hemodialysis, remains controversial but appears to be safe. As a last resort, extracorporeal life support might be considered in case of persisting hemodynamic instability.
  • Pleiotropic Effects of Tetracyclines in the Management of COVID-19: Emerging Perspectives. [Review]
    Front Pharmacol. 2021; 12:642822.Al-Kuraishy HM, Al-Gareeb AI, … El-Saber Batiha G
  • Coronavirus disease 2019 (COVID-19) is a global infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Approximately 15% of severe cases require an intensive care unit (ICU) admission and mechanical ventilation due to development of acute respiratory distress syndrome (ARDS). Tetracyclines (TCs) are a group of bacteriostatic antibiotics, like tetracycline, mino…
  • Current Overviews on COVID-19 Management Strategies. [Journal Article]
    Curr Pharm Biotechnol. 2021 May 08 [Online ahead of print]Rai PK, Mueed Z, … Poddar NK
  • The coronavirus pandemic has hit the world lately and caused acute respiratory syndrome in humans. The causative agent of the disease was soon brought to focus by scientists as SARS-CoV-2 and later called a novel coronavirus by the general public. Due to the severity and rapid spread of the disease, WHO classifies the COVID-19 pandemic as the 6th public health emergency even after taking efforts …
  • The interplay between the immune system and SARS-CoV-2 in COVID-19 patients. [Review]
    Arch Virol. 2021 May 05 [Online ahead of print]Shabbir S, Raza MH, … Khan MJ
  • Millions of people across the globe have been affected by coronavirus disease 2019 (COVID-19), which began in Wuhan, China, and is caused by SARS-CoV-2. COVID-19 has a variety of clinical characteristics and triggers immune responses required for the elimination of the viral agent. Currently, no effective treatment options are available for targeting SARS-CoV-2 infection. Repurposing of drugs suc…
  • Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents. [Review]
    Pediatr Rheumatol Online J. 2021 May 04; 19(1):68.Costagliola G, Spada E, Consolini R
  • CONCLUSIONS: The therapeutic approach to pediatric COVID-19 is multidisciplinary, and anti-rheumatic agents have a prominent role in severe disease. This paper reviews the rationale for the use of anti-rheumatic agents in pediatric COVID-19 and MIS-C and the clinical experience with the single drugs. Finally, the areas of potential improvement in the use of anti-rheumatic agents, including the optimization of the drug choice and the timing of administration, are discussed.
  • Impact of Treatment Regimens on Antibody Response to the SARS-CoV-2 Coronavirus. [Journal Article]
    Front Immunol. 2021; 12:580147.Shang Y, Liu T, … Zhou F
  • The coronavirus disease 2019 (COVID-19) is widely spread and remains a global pandemic. Limited evidence on the systematic evaluation of the impact of treatment regimens on antibody responses exists. Our study aimed to analyze the role of antibody response on prognosis and determine factors influencing the IgG antibodies' seroconversion. A total of 1,111 patients with mild to moderate COVID-19 sy…
  • Na+/K+-ATPase as a Target of Cardiac Glycosides for the Treatment of SARS-CoV-2 Infection. [Review]
    Front Pharmacol. 2021; 12:624704.Souza E Souza KFC, Moraes BPT, … Gonçalves-de-Albuquerque CF
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), identified for the first time in Wuhan, China, causes coronavirus disease 2019 (COVID-19), which moved from epidemic status to becoming a pandemic. Since its discovery in December 2019, there have been countless cases of mortality and morbidity due to this virus. Several compounds such as chloroquine, hydroxychloroquine, lopinavir-rito…
  • What if COVID-19 affects the child: which weapons and how to use them. [Review]
    Eur Rev Med Pharmacol Sci. 2021 Apr; 25(8):3325-3337.Anedda L, Bianchini L, … Marcialis MA
  • Since the reports in Wuhan (China), in December 2019, of the first cluster of cases of pneumonia caused by the new Coronavirus called 2019-nCoV or SARS-CoV-2, there has been a pandemic spread of the infection. By now, we have no specific therapy to counteract this emergency. The latest epidemiological data suggest that children are just as likely as adults to get infected by the virus. Most of th…
  • Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19. [Review]
    Int J Mol Sci. 2021 Apr 15; 22(8)Pereira GJDS, Leão AHFF, … Bincoletto C
  • The family of coronaviruses (CoVs) uses the autophagy machinery of host cells to promote their growth and replication; thus, this process stands out as a potential target to combat COVID-19. Considering the different roles of autophagy during viral infection, including SARS-CoV-2 infection, in this review, we discuss several clinically used drugs that have effects at different stages of autophagy…
  • Quinine Inhibits Infection of Human Cell Lines with SARS-CoV-2. [Journal Article]
    Viruses. 2021 04 09; 13(4)Groβe M, Ruetalo N, … Schubert U
  • While vaccination campaigns are ongoing worldwide, there is still a tremendous medical need for efficient antivirals against SARS-CoV-2 infection. Among several drug candidates, chloroquine (CQN) and hydroxychloroquine (H-CQN) were tested intensively, and any contentious therapeutic effect of both has been discussed controversially in the light of severe side effects and missing efficacy. Origina…
  • Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. [Journal Article]
    Viruses. 2021 04 02; 13(4)Werner J, Kronberg RM, … Lang PA
  • Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes COVID-19 and is responsible for the ongoing pandemic. Screening of potential antiviral drugs against SARS-CoV-2 depend on in vitro experiments, which are based on the quantification of the virus titer. Here, we used virus-induced cytopathic effects (CPE) in brightfield microscopy of SARS-CoV-2-infected monolayers to quantify the …
  • Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery. [Review]
    Int J Biol Sci. 2021; 17(6):1538-1546.Chen Y, Li MX, … Zhou J
  • The outbreak of coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly evolved into a global pandemic. One major challenge in the battle against this deadly disease is to find effective therapy. Due to the availability and proven clinical record of hydroxychloroquine (HCQ) and chloroquine (CQ) in various human diseases, there have been…
  • The role of CD4+FoxP3+ regulatory T cells in the immunopathogenesis of COVID-19: implications for treatment. [Review]
    Int J Biol Sci. 2021; 17(6):1507-1520.Wang Y, Zheng J, … Chen X
  • The severe cases of Coronavirus Disease 2019 (COVID-19) frequently exhibit excessive inflammatory responses, acute respiratory distress syndrome (ARDS), coagulopathy, and organ damage. The most striking immunopathology of advanced COVID-19 is cytokine release syndrome or "cytokine storm" that is attributable to the deficiencies in immune regulatory mechanisms. CD4+FoxP3+ regulatory T cells (Tregs…
  • The Rise and Fall of Hydroxychloroquine and Chloroquine in COVID-19. [Journal Article]
    J Pharm Pract. 2021 Apr 28 [Online ahead of print]Aljadeed R
  • On March 11th, the World Health Organization (WHO) announced the unprecedented outbreak of "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) to be a pandemic. Thus far, COVID-19 has infected over 58,229,138 individuals and caused 1,382,106 deaths worldwide. This has led to the re-purposing of available drugs under "off-label" use-drugs such as hydroxychloroquine and chloroquine. Both…
  • Prophylaxis against covid-19: living systematic review and network meta-analysis. [Meta-Analysis]
    BMJ. 2021 04 26; 373:n949.Bartoszko JJ, Siemieniuk RAC, … Brignardello-Petersen R
  • CONCLUSIONS: Hydroxychloroquine prophylaxis has trivial to no effect on hospital admission and mortality, probably increases adverse effects, and probably does not reduce the risk of SARS-CoV-2 infection. Because of serious risk of bias and very serious imprecision, it is highly uncertain whether ivermectin combined with iota-carrageenan and ivermectin alone reduce the risk of SARS-CoV-2 infection.
  • Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021). [Review]
    Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2021 Apr 23; 42(1):5-18.Panovska-Stavridis I, Ridova N, … Grozdanova A
  • The outbreak of the COVID-19 pandemic has generated the largest global health crisis of the 21st century, evolving into accelerating socioeconomic disruption. In spite of all rapidly and widely emerging scientific data on epidemiology, diagnosis, prevention and treatment of the COVID-19 disease, severe acute respiratory coronavirus 2 (SARS-CoV-2) is continuing to propagate in lack of definitive a…
New Search Next